Welcome to our dedicated page for Illumina news (Ticker: ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina stock.
Illumina Inc (NASDAQ: ILMN) is described by the company as a global leader in DNA sequencing and array-based technologies, serving research, clinical, and applied markets across genomics, multiomics, and proteomics. This news page aggregates recent press releases and announcements so readers can follow how Illumina’s technologies, collaborations, and financial disclosures evolve over time.
Company news highlights include product and platform launches, such as Illumina Connected Multiomics, a cloud-based software platform for analyzing and visualizing multiomic data, and Illumina Protein Prep, which the company states delivers broad coverage of the blood proteome and supports large-scale genomics studies. Illumina has also announced the Illumina Billion Cell Atlas, a large genome-wide genetic perturbation dataset developed through its BioInsight business to support AI-driven drug discovery in collaboration with pharmaceutical partners.
Investors can use this news feed to track Illumina’s preliminary financial results, earnings announcements, and capital markets activities, as reflected in press releases tied to quarterly and annual results and conference presentations. The page also captures updates on strategic agreements and acquisitions, including Illumina’s planned acquisition of Standard BioTools’ aptamer-based and functional proteomics business, as described in SEC filings and related communications.
In addition, Illumina’s news often covers leadership appointments, regulatory and market developments, and collaborations with genomics and population health partners such as MyOme. By reviewing these updates in one place, readers can better understand how Illumina positions its sequencing, multiomic, and proteomic offerings and how its corporate strategy and partnerships may influence its role in genomics and precision medicine. Bookmark this page to review new company-issued information as it becomes available.
Illumina, Inc. (NASDAQ: ILMN) has announced its participation in the 43rd Annual Cowen Health Care Conference on March 7, 2023. Executives will engage in a fireside chat scheduled for 6:50 AM Pacific Time (9:50 AM Eastern Time). The event will be accessible via a webcast on Illumina's website, with a replay available for 30 days post-event.
Illumina focuses on innovation and leadership in DNA sequencing and array-based technologies, impacting various sectors including life sciences and oncology. For more information, visit www.illumina.com.
John Hancock, a division of Manulife (NYSE: MFC), has expanded access to GRAIL's Galleri multi-cancer early detection test for eligible customers in its Vitality PLUS program. Following a successful pilot program in September 2022, this initiative aims to enhance preventative care, allowing customers aged 50 and over to benefit from early cancer detection, which is critical given that cancer is the second leading cause of death in the U.S. with an estimated 610,000 deaths in 2023. The Galleri test detects shared cancer signals across more than 50 cancer types through a blood draw, focusing on increasing awareness and access to innovative screening technologies.
GRAIL has partnered with PGA TOUR Champions player David Duval and Hall of Famer Juli Inkster to raise awareness about their Galleri multi-cancer early detection blood test, aimed at individuals over 50 or with elevated cancer risk. The test screens for signals across more than 50 cancer types with a low false positive rate of less than 1%. Duval's personal experience prompted him to advocate for proactive testing, while Inkster highlighted the importance of early detection in her family's cancer battle. This initiative coincides with the inaugural Galleri Classic tournament from March 20-26, 2023, supporting local cancer nonprofits.
Illumina's collaboration with NysnoBio aims to advance research on early-onset Parkinson's disease through the use of whole-genome sequencing (WGS). Led by CEO Jennifer Johnston, NysnoBio focuses on the Parkin protein, critical for managing cellular stress. Their research, funded by a grant from Aligning Sciences Across Parkinson's (ASAP), explores gene therapy to replace the Parkin gene in affected individuals. The team utilizes Illumina Connected Analytics to aggregate genomic data, aiming for personalized medicine. This innovative approach sets them apart in the search for effective therapies for this genetic form of Parkinson's.
Summary not available.
Illumina announced a strategic partnership with Admera Health, a genomic services laboratory, enhancing research capabilities in biopharma and healthcare. Founded in 2014, Admera specializes in sequencing and bioinformatics, retaining high-quality certifications. The partnership aims to utilize innovative sequencing technologies, including the NovaSeq 6000 and the newly ordered NovaSeq X Plus, to improve turnaround times and data quality for clients. This collaboration with top pharma and academic institutions positions Admera to support advanced genomic research and boost its business growth, focusing on biomarker discoveries and drug screenings.
On February 8, 2023, Illumina (NASDAQ: ILMN) announced the delivery of its first NovaSeq X Plus system to the Broad Institute during the AGBT conference in Hollywood, Florida. This marks a significant milestone for the company as it ramps up to ship 40-50 systems in the current quarter and more than 300 for the year. The NovaSeq X Plus offers enhanced throughput and accuracy, streamlining genomic research. Additionally, Illumina revealed updates on its Complete Long Reads technology, capable of producing highly accurate long reads with minimal DNA input. The market anticipates the launch of new products in 2023 aimed at advancing genomic capabilities.
Illumina (ILMN) reported Q4 2022 revenue of $1.08 billion, a 10% decrease from Q4 2021, and fiscal year revenue of $4.58 billion, up 1%. GAAP diluted loss per share was $(0.89) in Q4 2022 and $(28.00) for the full year. GRAIL segment recorded a significant goodwill impairment of $3.91 billion. Despite the challenges, the company anticipates 2023 revenue growth between 7% to 10% and expects GAAP diluted EPS of $0.03 to $0.28. CEO Francis deSouza emphasized strong customer interest in new products like the NovaSeq X and an increasing demand for GRAIL's Galleri test, with over 60,000 tests ordered to date.
Illumina marks World Cancer Day on February 4, 2023, by highlighting global efforts to close the cancer care gap. According to WHO, half of the world lacks access to essential health services, emphasizing the need for equitable cancer treatment. Illumina's chief medical officer, Phil Febbo, calls for improved access to treatments regardless of location. Various initiatives are showcased, including cancer screening outreach in Malaysia, educational tools in Brazil, advocacy for early detection in the US, and the establishment of precision oncology in Sweden. The company commends these organizations for their critical role in enhancing cancer care accessibility.
Illumina, Inc. (NASDAQ: ILMN) has appointed Joydeep Goswami as Chief Financial Officer, effective immediately. Previously serving as Chief Strategy and Corporate Development Officer and interim CFO since July 2022, Goswami's new role will involve overseeing financial planning, analysis, accounting, and investor relations. With over 20 years of experience in the life sciences industry, he aims to enhance shareholder value through improved financial operations. Francis deSouza, CEO of Illumina, expressed confidence in Goswami’s ability to drive growth, supported by a strong finance team.